427 related articles for article (PubMed ID: 25043744)
1. Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5.
Azoitei ML; Ban YA; Kalyuzhny O; Guenaga J; Schroeter A; Porter J; Wyatt R; Schief WR
Proteins; 2014 Oct; 82(10):2770-82. PubMed ID: 25043744
[TBL] [Abstract][Full Text] [Related]
2. Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope.
Azoitei ML; Ban YE; Julien JP; Bryson S; Schroeter A; Kalyuzhniy O; Porter JR; Adachi Y; Baker D; Pai EF; Schief WR
J Mol Biol; 2012 Jan; 415(1):175-92. PubMed ID: 22061265
[TBL] [Abstract][Full Text] [Related]
3. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
[TBL] [Abstract][Full Text] [Related]
4. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.
Julien JP; Huarte N; Maeso R; Taneva SG; Cunningham A; Nieva JL; Pai EF
J Virol; 2010 May; 84(9):4136-47. PubMed ID: 20147404
[TBL] [Abstract][Full Text] [Related]
5. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
Julien JP; Bryson S; Nieva JL; Pai EF
J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005
[TBL] [Abstract][Full Text] [Related]
6. Structural and Thermodynamic Basis of Epitope Binding by Neutralizing and Nonneutralizing Forms of the Anti-HIV-1 Antibody 4E10.
Rujas E; Gulzar N; Morante K; Tsumoto K; Scott JK; Nieva JL; Caaveiro JM
J Virol; 2015 Dec; 89(23):11975-89. PubMed ID: 26378169
[TBL] [Abstract][Full Text] [Related]
7. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.
Zwick MB; Komori HK; Stanfield RL; Church S; Wang M; Parren PW; Kunert R; Katinger H; Wilson IA; Burton DR
J Virol; 2004 Mar; 78(6):3155-61. PubMed ID: 14990736
[TBL] [Abstract][Full Text] [Related]
8. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.
Guenaga J; Wyatt RT
PLoS Pathog; 2012; 8(7):e1002806. PubMed ID: 22829767
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6.
Ofek G; Zirkle B; Yang Y; Zhu Z; McKee K; Zhang B; Chuang GY; Georgiev IS; O'Dell S; Doria-Rose N; Mascola JR; Dimitrov DS; Kwong PD
J Virol; 2014 Mar; 88(5):2426-41. PubMed ID: 24335316
[TBL] [Abstract][Full Text] [Related]
10. Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.
Tudor D; Yu H; Maupetit J; Drillet AS; Bouceba T; Schwartz-Cornil I; Lopalco L; Tuffery P; Bomsel M
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12680-5. PubMed ID: 22723360
[TBL] [Abstract][Full Text] [Related]
11. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.
Ofek G; McKee K; Yang Y; Yang ZY; Skinner J; Guenaga FJ; Wyatt R; Zwick MB; Nabel GJ; Mascola JR; Kwong PD
J Virol; 2010 Mar; 84(6):2955-62. PubMed ID: 20042512
[TBL] [Abstract][Full Text] [Related]
12. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold.
Azoitei ML; Correia BE; Ban YE; Carrico C; Kalyuzhniy O; Chen L; Schroeter A; Huang PS; McLellan JS; Kwong PD; Baker D; Strong RK; Schief WR
Science; 2011 Oct; 334(6054):373-6. PubMed ID: 22021856
[TBL] [Abstract][Full Text] [Related]
13. Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method.
Evans MC; Phung P; Paquet AC; Parikh A; Petropoulos CJ; Wrin T; Haddad M
BMC Bioinformatics; 2014 Mar; 15():77. PubMed ID: 24646213
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope.
Menendez A; Chow KC; Pan OC; Scott JK
J Mol Biol; 2004 Apr; 338(2):311-27. PubMed ID: 15066434
[TBL] [Abstract][Full Text] [Related]
15. Elicitation of structure-specific antibodies by epitope scaffolds.
Ofek G; Guenaga FJ; Schief WR; Skinner J; Baker D; Wyatt R; Kwong PD
Proc Natl Acad Sci U S A; 2010 Oct; 107(42):17880-7. PubMed ID: 20876137
[TBL] [Abstract][Full Text] [Related]
16. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints.
Tian Y; Ramesh CV; Ma X; Naqvi S; Patel T; Cenizal T; Tiscione M; Diaz K; Crea T; Arnold E; Arnold GF; Taylor JW
J Pept Res; 2002 Jun; 59(6):264-76. PubMed ID: 12010517
[TBL] [Abstract][Full Text] [Related]
17. Recognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicity.
Huarte N; Araujo A; Arranz R; Lorizate M; Quendler H; Kunert R; Valpuesta JM; Nieva JL
PLoS One; 2012; 7(12):e52740. PubMed ID: 23285173
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chain.
Almagro JC; Raghunathan G; Beil E; Janecki DJ; Chen Q; Dinh T; LaCombe A; Connor J; Ware M; Kim PH; Swanson RV; Fransson J
J Mol Recognit; 2012 Mar; 25(3):125-35. PubMed ID: 22407976
[TBL] [Abstract][Full Text] [Related]
19. A Comprehensive Study of Neutralizing Antigenic Sites on the Hepatitis E Virus (HEV) Capsid by Constructing, Clustering, and Characterizing a Tool Box.
Zhao M; Li XJ; Tang ZM; Yang F; Wang SL; Cai W; Zhang K; Xia NS; Zheng ZZ
J Biol Chem; 2015 Aug; 290(32):19910-22. PubMed ID: 26085097
[TBL] [Abstract][Full Text] [Related]
20. Construction of recombinant targeting immunogens incorporating an HIV-1 neutralizing epitope into sites of differing conformational constraint.
Ho J; MacDonald KS; Barber BH
Vaccine; 2002 Jan; 20(7-8):1169-80. PubMed ID: 11803079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
